Clinical Trials Logo

Hyperparathyroidism clinical trials

View clinical trials related to Hyperparathyroidism.

Filter by:

NCT ID: NCT02273570 Recruiting - Clinical trials for Hyperparathyroidism, Secondary

Optimal Anemia Treatment in End Stage Renal Disease (ERSD)

OPTIMAL
Start date: March 2015
Phase: N/A
Study type: Interventional

Clinical study aimed at improving anemia management in End Stage Renal Disease Patient (ESRD) on maintenance Hemodialysis with evidence of Chronic Kidney disease Mineral Bone Disorder (CKD-MBD)

NCT ID: NCT01783002 Recruiting - Clinical trials for Primary Hyperparathyroidism

11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues

Start date: May 2014
Phase: Phase 2
Study type: Interventional

The overall sensitivity and specificity of 11C-MET PET/CT is superior to 18F-FDG PET/CT and conventional SPECT-CT for the detection of abnormal parathyroid glands.

NCT ID: NCT01647503 Recruiting - Clinical trials for Primary Hyperparathyroidism

Differentially Expressed Proteins in Sporadic Parathyroid Tumors

Start date: July 2012
Phase: N/A
Study type: Observational

Primary hyperparathyroidism (PHPT) is one of the common endocrine disorders. The major clinical symptoms involve stones, bones, abdominal groans and psychiatric moans. Increased parathyroid cell proliferation and decreased calcium-mediated control of the PTH secretion are characteristic findings. The most common cause of PHPT is adenoma followed by hyperplasia and carcinoma.The molecular mechanisms involved in parathyroid tumorigenesis are partially known. Few genes have been identified and their roles are under study. The genes which are under study by different groups are unable to give a definite direction towards the understanding of parathyroid tumorigenesis and the mechanism involved in overgrowth of parathyroid tissue. So identifying different proteins and their regulation pattern from adenomas to carcinomas will be the initial steps towards understanding the proteins involved in tumorigenesis of parathyroid tissues. By using proteomics approach one can generate protein level information. In this study, using a combined approach based on 2 D gel electrophoresis and mass spectrometry (MS), the investigators propose to study a comparative proteomics to examine the changes of protein profiles in parathyroid tumor tissues with normal and hyperplasic parathyroid tissues. This work plan will help us to understand differentially expressed proteins in patients with PHPT. This will help in understanding the disease and identifying better diagnostic and curative measures of the disease. The investigators are also planning to access nuclear morphometry changes in sporadic parathyroid tumors. It will help in establishing cellular and nuclear change pattern variations from normal to parathyroid tumors.

NCT ID: NCT01479088 Recruiting - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)

Start date: March 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Twelve-month, multicenter, intra-subject controlled (retrospective-prospective), open-label, active-treatment study to evaluate the dose-response and pharmacokinetics (PK) of cinacalcet HCl for the treatment of Secondary Hyperparathyroidism (SHPT) in paediatric subjects with chronic kidney disease (CKD) on dialysis, followed by 12-month study extension.

NCT ID: NCT01228786 Recruiting - Clinical trials for Primary Hyperparathyroidism (PHPT)

Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism

Start date: October 2007
Phase: N/A
Study type: Observational

The present study is designed to examine the expression of VDR, CaSR, PTH, Cyclin D1, Ki67 and PCNA and to find out its relationship with clinical parameters in parathyroid adenomas. Examination of the contribution of genes expression can elucidate the critical link between proliferation and functional abnormalities in parathyroid adenomas. Alternative to DNA and RNA, protein expression can provide a better understanding of this disease.

NCT ID: NCT00973336 Recruiting - Clinical trials for Primary Hyperparathyroidism

Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?

Start date: September 2009
Phase: Phase 2
Study type: Interventional

Primary Hyperparathyroidism (pHPT) increases bone turnover and resorption and thus calcium efflux out of bone. After successful surgical treatment of pHPT, bone takes up calcium again which may result in secondary hyperparathyroidism or even "hungry bone syndrome". Until today there are no studies about this problem helping to develop recommendations or guidelines how to prevent these symptoms. Study hypothesis: Calcium and vitamin D intake after surgery for PHPT protects the bone by keeping PTH in the normal range (less secondary, reactive hyperparathyroidism), prevents hungry bone- syndrome and improve bone-turnover markers (osteoporosis protection).

NCT ID: NCT00452049 Recruiting - Hypertension Clinical Trials

The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure

Start date: April 2005
Phase: N/A
Study type: Observational

Secondary hyperparathyroidism (HPT) is a known complication of chronic renal failure. Elevated concentrations of parathyroid hormone (PTH) play a role not only in the pathogenesis of renal bone disease, but also in the development of cardiovascular risk factors such as disturbed lipid metabolism, glucose intolerance, and hypertension. HPT is also known to play an important role in the development of structural abnormalities of both large arteries and the heart (left ventricular hypertrophy, interstitial fibrosis). In the last couple of years there has been increasing evidence from animal studies that the endothelium is a target organ of PTH. Hypothesis: PTH has clinically relevant effects on renal hemodynamics, renal function and endothelial function. Aims: 1. To evaluate the effect of parathyroidectomy (PTX) on renal hemodynamics in stable renal transplant recipients 2. To evaluate the effect of PTX on endothelial function in stable renal transplant recipients/chronic kidney disease (CKD) stage 5 patients 3. To evaluate the effect of PTX on blood pressure in stable renal transplant recipients/CKD stage 5 patients

NCT ID: NCT00169806 Recruiting - Hyperparathyroidism Clinical Trials

Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis

Start date: November 1998
Phase: N/A
Study type: Interventional

Kidney stones are very common. They affect 3-5% of the population in the United States. Many people are hospitalized for the treatment of kidney stones and some may die. Better understanding of what causes kidney stones is useful in both the treatment and prevention of kidney stones. However, exactly what causes kidney stones is unknown. The most common type of kidney stones contains calcium, which sometimes is attached to a part of the kidney important in producing the final urine, called the papilla. The investigators have noticed that persons who form kidney stones seem to have more papilla with stones attached. They propose to study these areas of the papilla, called Randall's plaques (named after their discoverer), in patients undergoing surgery for kidney stones.